Abrdn World Healthcare Fund : 2025 Proxy Statement for HQH, HQL, THQ and THW (AA 150425 192051 2)

Published: 2025-04-24 17:24:07 ET THW

ABRDN HEALTHCARE INVESTORS ABRDN LIFE SCIENCES INVESTORS

ABRDN HEALTHCARE OPPORTUNITIES FUND

ABRDN WORLD HEALTHCARE FUND

1900 Market Street, Suite 200

Philadelphia, PA 19103

NOTICE OF ANNUAL MEETINGS OF SHAREHOLDERS

To be held on May 28, 2025

TO THE SHAREHOLDERS:

NOTICE IS HEREBY GIVEN that the annual meeting of shareholders of each of abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn Healthcare Opportunities Fund and abrdn World Healthcare Fund (each, a "Fund," and collectively, the "Funds") and any adjournments or postponements thereof will be held at the offices of abrdn Inc., located at 1900 Market Street, Suite 200, Philadelphia, PA 19103 (each meeting, an "Annual Meeting," and collectively, the "Annual Meetings") on the following dates and at the following times:

abrdn Healthcare Investors (NYSE: HQH)

May 28, 2025

12:30 p.m. Eastern Time

abrdn Life Sciences Investors (NYSE: HQL)

May 28, 2025

12:30 p.m. Eastern Time

abrdn Healthcare Opportunities Fund (NYSE: THQ)

May 28, 2025

12:30 p.m. Eastern Time

abrdn World Healthcare Fund (NYSE: THW)

May 28, 2025

12:30 p.m. Eastern Time

The purpose of the Annual Meetings is to consider and act upon the following proposals (each, a "Proposal") for each Fund, as applicable, and to consider and act upon such other matters as may properly come before the Annual Meetings or any adjournments or postponements thereof:

HQH - To elect two Class C Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

HQL - To elect two Class C Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

THQ - To elect two Class B Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

THW - To elect two Class A Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

Each Proposal is discussed in greater detail in the enclosed Joint Proxy Statement. You are entitled to notice of, and to vote at, the Annual Meeting of a Fund if you owned shares of such Fund at the close of business on April 7, 2025 (the "Record Date"). Even if you expect to attend an Annual Meeting, please complete, date, sign and return the enclosed proxy card(s) in the enclosed postage-paid envelope or authorize your proxy by telephone or through the Internet.

We will admit to an Annual Meeting (1) all shareholders of record on the Record Date, (2) persons holding proof of beneficial ownership on the Record Date, such as a letter or account statement from the person's broker, (3) persons who have been granted proxies, and (4) such other persons that we, in our sole discretion, may elect to admit. All persons wishing to be admitted to an Annual Meeting must present photo identification. If you plan to attend an Annual Meeting, we ask that you call us in advance at 1-800-522-5465.

This Notice and related proxy materials are first being mailed to shareholders on or about April 14, 2025.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meetings of Shareholders to Be Held on Weddnesday, May 28, 2025: This Notice, the Joint Proxy Statement and the form of proxy cards are available on the Internet at https://www.abrdnhqh.com (for HQH) https://www.abrdnhql.com (for HQL) https://www.abrdnthq.com (for THQ) and https://www.abrdnthw.com (for THW). On each Fund's website, you will be able to access the Notice, the Joint Proxy Statement, the form of proxy card(s) and any amendments or supplements to the foregoing materials that are required to be furnished to shareholders.

By order of the Boards of Trustees,

Megan Kennedy, Vice President and Secretary abrdn Healthcare Investors

abrdn Life Sciences Investors

abrdn Healthcare Opportunities Fund abrdn World Healthcare Fund

TO AVOID THE UNNECESSARY EXPENSE OF FURTHER SOLICITATION, WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETINGS, IT IS IMPORTANT THAT YOUR SHARES BE REPRESENTEDANDVOTEDATTHEANNUALMEETINGS.ACCORDINGLY,YOUAREREQUESTED TO PLEASE DATE, SIGN AND RETURN THE ENCLOSED PROXY CARD(S) FOR THE ANNUAL MEETINGS PROMPTLY, OR TO AUTHORIZE THE PROXY VOTE BY TELEPHONE OR THROUGH THE INTERNET PURSUANT TO THE INSTRUCTIONS ON THE ENCLOSED PROXY CARD(S). NO POSTAGE IS REQUIRED IF MAILED IN THE UNITED STATES. IT IS IMPORTANT THAT YOUR PROXY CARD(S) BE RETURNED PROMPTLY IN ORDER TO AVOID THE ADDITIONAL EXPENSE OF FURTHER SOLICITATION.

April 14, 2025

Philadelphia, Pennsylvania

ABRDN HEALTHCARE INVESTORS ("HQH") ABRDN LIFE SCIENCES INVESTORS ("HQL")

ABRDN HEALTHCARE OPPORTUNITIES FUND ("THQ")

ABRDN WORLD HEALTHCARE FUND ("THW")

(each, a "Fund" and collectively, the "Funds")

1900 Market Street, Suite 200

Philadelphia, PA 19103

JOINT PROXY STATEMENT

For the Annual Meetings of Shareholders

each to be held on May 28, 2025

This Joint Proxy Statement is furnished in connection with the solicitation of proxies by each Fund's Board of Trustees (each, a "Board," and collectively, the "Boards," with members of each Board being referred to as "Trustees") to be voted at the Annual Meeting of Shareholders of each Fund (each, a "Meeting," and collectively, the "Meetings") and at any adjournments or postponements thereof to be held at the offices of abrdn Inc., located at 1900 Market Street, Suite 200, Philadelphia, PA 19103 on the following dates and at the following times:

abrdn Healthcare Investors (NYSE: HQH)

May 28, 2025

12:30 p.m. Eastern Time

abrdn Life Sciences Investors (NYSE: HQL)

May 28, 2025

12:30 p.m. Eastern Time

abrdn Healthcare Opportunities Fund (NYSE: THQ)

May 28, 2025

12:30 p.m. Eastern Time

abrdn World Healthcare Fund (NYSE: THW)

May 28, 2025

12:30 p.m. Eastern Time

A Notice of Annual Meetings of Shareholders and a proxy card (the "Proxy Card") accompany this Joint Proxy Statement. This Joint Proxy Statement is first being mailed on or about April 14, 2025 to shareholders of record as of April 7, 2025.

The purpose of each Meeting is to consider and act upon the following proposals (each a "Proposal"), as applicable to each Fund:

HQH - To elect two Class C Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

HQL - To elect two Class C Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

THQ - To elect two Class B Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

THW - To elect two Class A Trustees to serve until the 2028 Annual Meeting of Shareholders or until such Trustee's successor is duly elected and qualified.

All properly executed proxies received prior to a Meeting will be voted at that Meeting, or at any adjournments or postponements thereof, in accordance with the instructions marked on the Proxy Card. Unless instructions to the contrary are marked on the Proxy Card, proxies received will be voted "FOR" each Proposal. The persons named as proxy holders on the Proxy Card will vote in their discretion on any other matters that may properly come before each Meeting or any adjournments or postponements thereof. Any Proxy Card may be revoked at any time prior to its exercise by submitting a properly executed, subsequently dated Proxy Card,

giving written notice to Megan Kennedy, Secretary of the Fund(s), 1900 Market Street, Suite 200, Philadelphia, PA 19103, or by attending a Meeting and voting in person. Shareholders may authorize proxy voting by using the enclosed Proxy Card along with the enclosed envelope with pre-paid postage. Shareholders may also authorize proxy voting by telephone or through the internet by following the instructions contained on the Proxy Card. Shareholders do not have dissenter's rights of appraisal in connection with any of the matters to be voted on by the shareholders at each Meeting.

In order to transact business at the Meetings, a "quorum" must be present for each Meeting. Under each Fund's By-laws, a quorum is constituted by the presence in person or by proxy of the holders of a majority of the outstanding shares of the respective Fund on the record date. Abstentions and broker non-votes (i.e., proxies from brokers or nominees indicating that they have not received instructions from the beneficial owners on an item for which the brokers or nominees do not have discretionary power to vote) will be treated as present for determining whether a quorum is present with respect to a particular matter at a Meeting.

The election of a Trustee to a Board requires the affirmative vote of a plurality of the shares entitled to vote for the election of any Trustee present or represented by proxy at a Meeting with a quorum present. Under a plurality vote, the nominees who receive the highest number of votes will be elected even if they receive less than a majority of the votes. There will be no cumulative voting with respect to the proposal. For purposes of the election of Trustees, abstentions and broker non-votes will be counted as shares present for quorum purposes, but will not be treated as votes cast. Abstentions and broker non-votes, therefore, will have no effect on the election of the Trustees. All properly executed proxies received prior to the Meetings will be voted, at the Meetings or at any adjournments or postponements thereof, in accordance with the instructions marked thereon. Proxies received prior to the Meetings on which no vote is indicated will be voted "FOR" the election of the Trustees.

Brokers holding shares of a Fund in "street name" for the benefit of their customers and clients will request the instructions of such customers and clients on how to vote their shares before the Meetings. Under the rules of the New York Stock Exchange ("NYSE"), such brokers may, for certain "routine" matters, grant discretionary authority to the proxies designated by a Board to vote if no instructions have been received from their customers and clients prior to the date specified in the brokers' request for voting instructions. Each Proposal is a "routine" matter and accordingly beneficial owners who do not provide proxy instructions or who do not return a proxy card may have their shares voted by broker-dealer firms in favor of the Proposal.

The chair of a Meeting shall have the power to adjourn the Meeting without further notice other than announcement at that Meeting. Each Board of Trustees also has the power to postpone a Meeting to a later date and/or time or change the place of a Meeting (including by specifying that the Meeting will be held by remote communication) one or more times for any reason by giving, within a reasonable period of time prior to such Meeting, notice to each shareholder entitled to vote at such Meeting of the place (including that the Meeting will be held by remote communication), date and hour at which such Meeting will be held. Such notice shall be given not fewer than two (2) days before the date of such Meeting and otherwise in accordance with each Fund's By-Laws. No notice of adjournment of a Meeting to another time or place need be given to shareholders. Abstentions and broker non-votes will have the same effect at any adjourned or postponed meeting as noted above. Any business that might have been transacted at a Meeting may be transacted at any such adjourned or postponed session(s) at which a quorum is present.

We will admit to each Meeting (1) all shareholders of record on April 7, 2025 (the "Record Date"),

of a shareholder of record, you must bring a form of personal identification to the Meeting, where your name will be verified against our shareholder list. If a broker or other nominee holds your shares and you plan to attend a Meeting, you should bring a recent brokerage statement showing your ownership of the shares, as well as a form of personal identification. If you are a beneficial owner and plan to vote at a Meeting, you should also bring a proxy card from your broker.

Each Board has fixed the close of business on April 7, 2025 as the Record Date for the determination of shareholders entitled to notice of, and to vote at, each Meeting and at any adjournment or postponement thereof.

Each Fund has one class of shares, par value $0.01 per share. Each share of a Fund is entitled to one vote at the Meeting, and fractional shares are entitled to a proportionate share of one vote. On the Record Date, the following number of shares of each Fund were issued and outstanding:

HQH 53,862,184.0

HQL 28,872,416.0

THQ 41,379,166.7

THW 39,849,957.6

Important Notice Regarding the Availability of Proxy Materials for the Meetings to Be Held on Wednesday, May 28, 2025: The Proxy Materials and each Fund's most recent annual report for the fiscal year ended September 30, 2024 are available on the Internet at https://www.abrdnhqh.com (for HQH) https://www.abrdnhql.com (for HQL) https://www.abrdnthq.com (for THQ) and https://www.abrdnthw.com (for THW). Each Fund will furnish, without charge, a copy of its annual report for the fiscal year ended September 30, 2024 and any more recent reports, to any Fund shareholder upon request. To request a copy, please write to the Funds c/o abrdn Inc., 1900 Market Street, Suite 200, Philadelphia, PA 19103, or call 1-800-522-5465. You may also call for information on how to obtain directions to be able to register to attend a Meeting.

The Election of Trustees

Each Fund's Declaration of Trust, as amended to date (the "Declaration of Trust"), provides that its Board shall be divided into three classes with staggered terms. The term of office of each Class of Trustees for each Fund will expire in the year indicated in the following chart:

Fund

Class A

Class B

Class C

HQH

2026

2027

2028

HQL

2026

2027

2028

THQ

2027

2028

2026

THW

2028

2026

2027

Each Fund's Declaration of Trust provides that a majority of its Trustees shall fix the number of the entire Board of Trustees and that such number shall be at least three and no greater than fifteen. Each Fund's Board has fixed the number of Trustees at six. Proxies will be voted for the election of the following nominees for HQH, HQL, THQ and THW. In the event that a nominee is unable to serve for any reason when the election occurs, the accompanying Proxy will be voted for such other person or persons as the applicable Fund's Board may recommend. Each nominee is presently serving as a Trustee.

Each Board, including the Independent Trustees, upon the recommendation of such Board's Nominating and Corporate Governance Committee, which is composed entirely of Independent Trustees, has nominated the following nominees as Trustees to its Board:

abrdn Healthcare Investors

Kathleen Goetz (Class C Trustee, 3 year term ending 2028)

Todd Reit (Class C Trustee, 3 year term ending 2028)

abrdn Life Sciences Investors

Rose DiMartino (Class C Trustee, 3 year term ending 2028)

Todd Reit (Class C Trustee, 3 year term ending 2028)

abrdn Healthcare Opportunities Fund

Rose DiMartino (Class B Trustee, 3 year term ending 2028)

C. William Maher (Class B Trustee, 3 year term ending 2028)

abrdn World Healthcare Fund

Kathleen Goetz (Class A Trustee, 3 year term ending 2028)

Christian Pittard (Class A Trustee, 3 year term ending 2028)

Each nominee has indicated an intention to serve as Trustee if elected and has consented to be named in this Joint Proxy Statement.

It is the intention of the persons named as proxies on the enclosed Proxy Card(s) to vote "FOR" the election of the nominees for each Class of Trustee to serve for a three-year term. In the event that a nominee is unable to serve for any reason when the election occurs, the proxies received will be voted for such substituted nominees as such Board may recommend.

The following tables set forth certain information regarding the nominees for election to the Boards of the Funds, Trustees whose terms of office continue beyond the Meetings, and the principal officers of the Funds. abrdn Inc., its parent company Aberdeen Group plc (formerly, abrdn plc), and its advisory affiliates are collectively referred to as "abrdn" in the tables below.

Number of

Registrants

Other

in Fund

Directorships

Position(s)

Term of Office

Principal Occupation(s)

Complex*

Held by Trustee

Name, Address and

Held with

and Length of

During at Least the

Overseen by

or Nominee for

Year of Birth

Fund

Time Served

Past Five Years

Trustee

Independent Trustee:

Jeffrey A. Bailey** †

Class A

Term expires

c/o abrdn Inc.

Trustee

2026 (HQH and

1900 Market Street,

(HQH);

THQ); and 2027

Suite 200

Class B

(HQL and THW)

Philadelphia, PA 19103

Trustee

Trustee of each

Year of Birth: 1962

(HQL);

Fund since 2020

Class C

Trustee (THQ

and THW)

Mr. Bailey was the CEO of

4 Registrants

None

IllummOss Inc from

consisting of

2018-2020. He also served

4 Portfolios

as the Board Chairman of

Aileron Therapeutics Inc.

2017-2024 and Independent

Board Chair of Tekla Funds

2020-2023. Most recently

he served as the Director

and CEO of BioDelivery

Systems, Inc. from

2020-2022. He currently

also serves on the board of

Aurinia Pharmaceuticals.

Number of

Registrants

Other

in Fund

Directorships

Position(s)

Term of Office

Principal Occupation(s)

Complex*

Held by Trustee

Name, Address and

Held with

and Length of

During at Least the

Overseen by

or Nominee for

Year of Birth

Fund

Time Served

Past Five Years

Trustee

Nominees for Independent Trustee:

Kathleen Goetz** †

Class A

Term expires

Independent Consultant

4 Registrants

c/o abrdn Inc.

Trustee (HQL,

2025 (2028, if

(since 2020); Novartis

consisting of

1900 Market Street,

THQ and

elected) (HQH

Pharmaceuticals: Vice

4 Portfolios

Suite 200

THW);

and THW); 2026

President and Head of Sales

Philadelphia, PA 19103

Class C

(HQL); and 2027

(2017-2019), Executive

Year of Birth: 1966

Trustee

(THQ)

Director of Strategic

(HQH)

Trustee of each

Account Management

(2015-2016).

Fund since 2021

Rose DiMartino** †

Class B

Term expires

Ms. DiMartino has been

6 Registrants

None.

c/o abrdn Inc.

Trustee (HQH,

2025 (2028, if

retired since 2019.

consisting of

1900 Market Street,

THQ and

elected) (HQL

Previously, she was Partner

8 Portfolios

Suite 200

THW);

and THQ); 2026

(1991-2017) and Senior

Philadelphia, PA 19103

Class C

(THW); and 2027

Counsel (2017-2019) at the

Year of Birth: 1952

Trustee (HQL)

(HQH);

law firm of Willkie Farr &

Trustee of each

Gallagher LLP

Fund since 2023

C. William Maher** †

Class A

Term expires

Mr. Maher is a Co-founder

7 Registrants

None.

c/o abrdn Inc.

Trustee

2025 (2028, if

of Asymmetric Capital

consisting of

1900 Market Street,

(HQL);

elected) (THQ);

Management LLC from

7 Portfolios

Suite 200

Class B

2026 (HQL); and

May 2018 to

Philadelphia, PA 19103

Trustee (HQH

2027 (HQH and

September 2020. Formerly

Year of Birth: 1961

and THQ);

THW);

Chief Executive Officer of

Class C

Trustee of each

Santa Barbara Tax Products

Trustee

Group from October 2014

Fund since 2023

(THW)

to April 2016.

Todd Reit** †

Chair of the

Term expires 2025

Mr. Reit is a Managing

9 Registrants

None.

c/o abrdn Inc.

Board

(2028, if elected)

Member of Cross Brook

consisting of

1900 Market Street,

Class A

(HQH and HQL);

Partners LLC, a real estate

9 Portfolios

Suite 200

2026 (THW); and

investment and management

Trustee

Philadelphia, PA 19103

2027 (THQ)

company since 2017.

(THQ);

Year of Birth: 1968

Mr. Reit is also Director and

Class B

Trustee of each

Financial Officer of Shelter

Trustee

Fund since 2023

Our Soldiers, a charity to

(THW);

support military veterans,

Class C

since 2016. Mr. Reit was

Trustee (HQH

formerly a Managing

and HQL)

Director and Global Head of

Asset Management

Investment Banking for

UBS AG, where he was

responsible for overseeing all

the bank's asset management

client relationships globally,

including all corporate

security transactions,

mergers and acquisitions.

Mr. Reit retired from UBS in

Number of

Registrants

Other

in Fund

Directorships

Position(s)

Term of Office

Principal Occupation(s)

Complex*

Held by Trustee

Name, Address and

Held with

and Length of

During at Least the

Overseen by

or Nominee for

Year of Birth

Fund

Time Served

Past Five Years

Trustee

2017 after an over 25-year career at the company and its predecessor company, PaineWebber Incorporated (merged with UBS AG in 2000).

Nominee for Interested Trustee:

Christian Pittard††

Class A

Term expires

Mr. Pittard is Head of

12 Registrants None.

c/o abrdn Inc.

Trustee (HQH

2025 (2028 if

Closed End Funds for abrdn

consisting of

1900 Market St.,

and THW);

elected) (THW);

responsible for the US and

12 Portfolios

Suite 200,

Class B

2026 (HQH and

UK businesses. He is also

Philadelphia, PA 19103

THQ); and 2027

Managing Director of

Year of Birth: 1973

Trustee

(HQL)

Corporate Finance having

(HQL);

done a significant number

Trustee of each

Class C

of closed end fund

Fund since 2024

transactions in the US and

Trustee (THQ)

UK since joining abrdn in

1999. Previously, he was

Head of the Americas and

the North American Funds

business based in the US.

ADDITIONAL INFORMATION ABOUT THE TRUSTEES

The Boards believe that each Trustee's experience, qualifications, attributes and skills on an individual basis and in combination with those of other Trustees lead to the conclusion that each Trustee should serve in such capacity. Among the attributes or skills common to all Trustees are their ability to review critically and to evaluate, question and discuss information provided to them, to interact effectively with the other Trustees, the Fund's investment adviser, the administrator and other service providers, counsel and independent registered public accounting firm, and to exercise effective and independent business judgment in the performance of their duties as Trustees. Each Trustee's ability to perform the duties of a trustee effectively has been attained and enhanced through the Trustee's education, professional training and other life experiences, such as business, consulting or public service positions and through experience from service as a member of each Fund's Board, public companies, or non- profit entities or other organizations.

OFFICERS

Term of Office*

Name, Address and

Position(s) Held

and Length of

Year of Birth

With the Funds

Time Served

Principal Occupation(s) During Past Five Years

Joseph Andolina**

Chief

Since 2023

Currently, Chief Risk Officer-Americas and serves as the

c/o abrdn Inc.

Compliance

Chief Compliance Officer for abrdn Inc. Prior to joining the

1900 Market St, Suite 200

Officer;

Risk and Compliance Department, he was a member of abrdn

Philadelphia, PA 19103

Vice President,

Inc.'s Legal Department, where he served as U.S. Counsel

Year of Birth: 1978

Compliance of

since 2012.

the Funds

Jason Akus**

Vice President of

Since 2023

Currently Senior Investment Director. Dr. Akus joined abrdn

abrdn Inc.

the Funds

Inc in October 2023 from Tekla Capital Management where he

28 State Street

was employed as a senior vice president of research.

17th Floor

Boston, MA 02109

Year of Birth: 1974

Josh Duitz**

Vice President of

Since 2023

Currently, Head of Global Income at abrdn, Inc. Mr. Duitz

abrdn Inc.

the Funds

joined abrdn Inc. in 2018 from Alpine Woods Capital

875 Third Ave

Investors LLC where he was a Portfolio Manager.

4th Floor, Suite 403

New York, NY 10022

Year of Birth: 1970

Sharon Ferrari**

Treasurer and

Since 2023

Currently, Director Product Management-US for abrdn Inc.

c/o abrdn Inc.

Chief Financial

Ms.Ferrari joined abrdn Inc. as a Senior Fund Administrator in

1900 Market St, Suite 200

Officer

2008.

Philadelphia, PA 19103

Year of Birth: 1977

Katie Gebauer**

Vice President of

Since 2025

Currently, Chief Compliance Officer-ETFs. Ms. Gebauer

c/o abrdn Inc.

the Funds

joined abrdn Inc. in 2014.

1900 Market St, Suite 200

Philadelphia, PA 19103

Year of Birth: 1986

Alan Goodson**

President of the

Since 2023

Currently, Director, Vice President and Head of Product&

c/o abrdn Inc.

Funds

Client Solutions-Americas for abrdn Inc., overseeing Product

1900 Market Street,

Management& Governance, Product Development and Client

Suite 200

Solutions for registered and unregistered investment

Philadelphia, PA 19103

companies in the U.S., Brazil and Canada. Mr.Goodson is

Year of Birth: 1974

Director and Vice President of abrdn Inc. and joined abrdn

Inc. in 2000.

Heather Hasson**

Vice President of

Since 2025

Currently, Senior Product Solutions and Implementation

c/o abrdn Inc.

the Funds

Manager, Product Governance US for abrdn Inc. Ms. Hasson

1900 Market St, Suite 200

joined abrdn Inc. as a Fund Administrator in 2006.

Philadelphia, PA 19103

Year of Birth: 1982

Robert Hepp**

Vice President of

Since 2025

Currently, Senior Product Governance Manager, Product

c/o abrdn Inc.

the Funds

Governance US at abrdn Inc. Mr. Hepp joined abrdn Inc.

1900 Market Street,

in 2016.

Suite 200

Philadelphia, PA 19103

Year of Birth: 1986

Term of Office*

Name, Address and

Position(s) Held

and Length of

Year of Birth

With the Funds

Time Served

Principal Occupation(s) During Past Five Years

Megan Kennedy**

Vice President of

Since 2023

Currently, Senior Director, Product Governance for abrdn Inc.

c/o abrdn Investments

the Funds

Ms. Kennedy joined abrdn Inc. in 2005.

Limited

c/o abrdn Inc.

1900 Market Street,

Suite 200

Philadelphia, PA 19103

Year of Birth: 1974

Andrew Kim**

Vice President of

Since 2025

Currently, Senior Product Governance Manager, Product

c/o abrdn Inc.

the Funds

Governance US for abrdn Inc. Mr. Kim joined abrdn Inc.

1900 Market Street,

in 2013.

Suite 200

Philadelphia, PA 19103

Year of Birth: 1983

Michael Marsico**

Vice President of

Since 2025

Currently, Senior Product Manager-US for abrdn.

c/o abrdn Inc.

the Funds

Mr. Marsico joined abrdn Inc. in 2014.

1900 Market Street,

Suite 200

Philadelphia, PA 19103

Year of Birth: 1980

Ben Ritchie**

Vice President of

Since 2023

Currently Head of the Developed Markets Equity team at

abrdn Investments Limited

the Funds

abrdn.

280 Bishopsgate

London, E2M 4AG

Year of Birth: 1980

Christian Pittard**

Vice President of

Since 2023

Currently, Director of Corporate Finance and Head of Listed

c/o abrdn Investments

the Funds

Funds. Mr. Pittard joined abrdn from KPMG in 1999.

Limited

280 Bishopsgate

London, EC2M 4AG

Year of Birth: 1973

Kolotiolomq Silue**

Vice President of

Since 2024

Currently, Senior Product Manager for abrdn Inc. Mr. Silue

c/o abrdn Inc.

the Funds

joined abrdn Inc in October 2023 from Tekla Capital

1900 Market St, Suite 200

Management where he was employed as a Senior Manager of

Philadelphia, PA 19103

Fund Administration.

Year of Birth: 1977

Lucia Sitar**

Vice President of

Since 2023

Currently, Vice President and Head of Product Management

c/o abrdn Inc.

the Funds

and Governance for abrdn Inc. since 2020. Previously

1900 Market St, Suite 200

Ms. Sitar was Managing U.S. Counsel for abrdn Inc. Ms. Sitar

Philadelphia, PA 19103

joined abrdn Inc. as U.S. Counsel in July 2007.

Year of Birth: 1971

Michael Taggart**

Vice President of

Since 2023

Currently, Closed End Fund Specialist at abrdn Inc since 2023.

c/o abrdn Inc.

the Funds

Prior to that, he was Vice President of Investment Research

1900 Market St, Suite 200

and Operations at Relative Value Partners, LLC from

Philadelphia, PA 19103

June 2022. Prior to that, he was self-employed after having

Year of Birth: 1970

left Nuveen in November 2020, where he had served as Vice

President of Closed-End Fund Product Strategy since

November 2013.

Disclaimer

abrdn World Healthcare Fund published this content on April 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2025 at 21:23 UTC.